News >

Treatment-Related AEs Can Require Careful Management in Patients With RCC

Caroline Seymour
Published: Wednesday, Jan 02, 2019

Heather Greene, NP

Heather Greene, NP
The treatment-related adverse events (TRAEs) associated with VEGF TKIs, mTOR inhibitors, and immunotherapy agents are easily managed more often than not in metastatic renal cell carcinoma (RCC), explained Heather Greene, NP.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x